A phase I/II trial (TIGER-X; NCT01526928) of rociletinib was performed in patients with EGFR-mutant NSCLC with acquired resistance to first- or second-generation EGFR TKIs (40). Here, EGFR is linked to non-small cell lung carcinoma.